Latest Breaking News On - International society for apheresis - Page 1 : comparemela.com

Share: Immunopheresis TM is shown to be well-tolerated in treating cancer patients who failed multiple lines of standard therapies Immunicom, Inc., a clinical-stage biotechnology company pioneering subtractive advanced cancer therapies, presented promising preliminary data from trials investigating Immunopheresis TM therapy for metastatic, refractory, solid tumor cancer patients who previously failed multiple lines of therapy. The results presented by Immunicom s Chief Medical Officer, Dr. Robert Segal, at the 2021 ISFA/E-ISFA virtual joint conference established that Immunopheresis administered to end-stage cancer patients was generally well-tolerated and has the potential for treating refractory malignancies. Immunicom s novel Immunopheresis therapy uses its proprietary subtractive LW-02 column to selectively remove immune-suppressive cytokines produced by cancer tumors (Photo: Business Wire)

San diegoUnited statesTel avivRobert segalGokhan demirGal markelRonnie shapiraPiotr wysockiBristol myers squibbZamir jafriEuropean groupImmunicom incJagiellonian university of krakow hospitalDrug administrationInternational society for apheresisHealthcare group